SlidesetHIVSpanish HIV Clinical Forum 2017Experiencia con Inhibidores de la Integrasa en un hospital terciario- I. MurView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Dolutegravir (DTG) based antiretroviral therapy (ART) discontinuation in clinical practice- V. Moreno-TorresView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Reasons for discontinuation of dual therapy with dolutegravir and riplivirine- R. MontejanoView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Dolutegravir and lamivudine as dual maintenance therapy- R. MontejanoView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Eficacia y seguridad de dolutegravir más rilpivirina en la vida real. Resultados a 24 semanas. Estudio DORIVIR- J. SantosView Slideset
CBCharles BoucherMD, PhDSlidesetHIVSpanish HIV Clinical Forum 2017HIV Prevention 2.0- Charles Boucher, MD, PhDView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Clinical case on reduced drug regimen with integrase inhibitors- Federico Pulido, MDView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Toxicity and co-morbidities perspective- José Ignacio Bernardino, MDView Slideset
JMJosé MoltóMD, PhDSlidesetHIVSpanish HIV Clinical Forum 2017Pharmacological perspective- José Moltó, MD, PhDView Slideset
JSJonathan SchapiroMDSlidesetHIVSpanish HIV Clinical Forum 2017Reduced drug regimens, what’s the magic number: three, two or one? – Overview- Jonathan Schapiro, MDView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2017Transmisión de mutaciones de resistencias a inhibidores de la integrasa- I. VicianaView Slideset
